Home Stock

Stock Research: Corcept Therapeutics

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Corcept Therapeutics

NAQ:CORT US2183521028
57
  • Value
    4
  • Growth
    94
  • Safety
    Safety
    30
  • Combined
    38
  • Sentiment
    93
  • 360° View
    360° View
    57
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Corcept Therapeutics Incorporated is a commercial-stage company that develops medications to treat severe disorders by modulating the effects of the hormone cortisol. The company operates in the pharmaceutical industry, marketing Korlym (mifepristone) in the United States. In the last fiscal year, the company had a market cap of $7,599 million, profits of $664 million, and revenue of $675 million with 500 employees.

more

ANALYSIS: With an Obermatt 360° View of 58 (better than 58% compared with alternatives), overall professional sentiment and financial characteristics for the stock Corcept Therapeutics are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Corcept Therapeutics. The consolidated Growth Rank has a good rank of 100, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 100% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 81, which means that professional investors are more optimistic about the stock than for 81% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 4, which means that the share price of Corcept Therapeutics is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 96% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 36, which means that the company has a financing structure that is riskier than those of 64% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Growth
Country USA
Industry Pharmaceuticals
Size Medium
Website corcept.com
Index
NASDAQ
Corcept Therapeutics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 8-Jun-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
4 1 1 19
Growth
94 100 91 29
Safety
Safety
30 35 99 99
Sentiment
93 84 61 62
360° View
360° View
57 27 16 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
45 75 44 13
Opinions Change
82 72 25 50
Pro Holdings
n/a 82 73 98
Market Pulse
81 35 62 52
Sentiment
93 84 61 62
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
4 1 1 19
Growth
94 100 91 29
Safety Safety
30 35 99 99
Combined
38 15 74 74
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
42 7 18 22
Price vs. Earnings (P/E)
1 27 19 52
Price vs. Book (P/B)
7 9 9 30
Dividend Yield
1 1 1 1
Value
4 1 1 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
75 81 75 39
Profit Growth
79 74 37 39
Capital Growth
97 100 89 61
Stock Returns
43 100 85 41
Growth
94 100 91 29
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
77 100 100 100
Refinancing
46 20 33 41
Liquidity
1 1 86 86
Safety Safety
30 35 99 99

Similar Stocks

Discover high‑ranked alternatives to Corcept Therapeutics and broaden your portfolio horizons.

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Penske Automotive

NYQ:PAG
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Academy Sports and Outdoors

NSQ:ASO
Country: USA
Industry: Specialty Stores
Size: Large
Full Stock Analysis

Five9

NMQ:FIVN
Country: USA
Industry: Application Software
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews